Short answer
CareDx, Inc. (CDNA) filed its Q2 2026 10-Q quarterly report on Jul 30, 2026 for the quarter ended Jun 30, 2026. Quarterly revenue was $132M (up 52.2% year over year) with net income of $111M.
Q2 2026 key financials · XBRL
- Revenue
- $132M
- +52.2% YoY · +12.1% QoQ
- Net income
- $111M
- +1391.3% YoY · +3838.6% QoQ
- Operating margin
- 85.8%
- EPS (diluted)
- $2.08
- +1400.0% YoY · +4060.0% QoQ
Source: XBRL data from the CareDx, Inc. (CDNA) Q2 2026 10-Q on SEC EDGAR. USD.
CareDx, Inc. Q2 2026 10-Q analysis
AI summary of MD&A and risk factor updates
Risk Factors
- New Medicare compliance trigger: 2026 legislation requires private-payor rate reporting to CMS during May–July 2026
- Medicare concentration: testing revenue 37% and total revenue 30% from Medicare during the quarter
- Regulatory coverage risk: Final LCD effective August 30, 2026 preserves coverage but imposes defined criteria for transplant testing
- Competitive adoption risk: Natera and Eurofins offer commercially available molecular transplant-surveillance diagnostics
- Profitability risk: $110.6 million quarterly net income versus $505.4 million accumulated deficit
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other CareDx, Inc. quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.